Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Kyu Taek Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2233-3511; OpenAlex author ID A5001027928. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers

Papers 26

  1. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  2. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  3. Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing. Co-author DOI 10.3343/alm.2025.0121↗
  4. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  5. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adeno… Co-author DOI 10.1016/j.gie.2024.02.021↗
  6. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma an… Co-author DOI 10.1186/s12943-024-02003-0↗
  7. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.1101/2023.02.15.23286007↗
  8. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04549-x↗
  9. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.21203/rs.3.rs-2578124/v1↗
  10. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101321↗
  11. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  12. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. Co-author DOI 10.3390/cancers13112791↗
  13. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Co-author DOI 10.3389/fonc.2020.616440↗
  14. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5009/gnl19011↗
  15. Comparison of 22-gauge standard fine needle versus core biopsy needle for endoscopic ultrasound-guided sampling of suspected pancreatic cancer: a randomized cr… Co-author DOI 10.1080/00365521.2017.1390597↗
  16. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcino… Co-author DOI 10.18632/oncotarget.13864↗
  17. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Last author DOI 10.1097/mpa.0000000000000346↗
  18. KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells. First author PMID 25550550↗
  19. KML001 inhibits cell proliferation and invasion in pancreatic cancer cells through suppression of NF-κB and VEGF-C. Co-author PMID 24982355↗
  20. Clinicoradiologic characteristics and outcomes of metastatic cancer to the pancreas and double primary pancreatic cancer. Co-author DOI 10.1016/j.clinre.2012.05.013↗
  21. The differentiation of autoimmune pancreatitis and pancreatic cancer using imaging findings. Co-author DOI 10.5754/hge11946↗
  22. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Co-author DOI 10.1097/coc.0b013e31821a83d7↗
  23. New-onset diabetes patients need pancreatic cancer screening? Co-author DOI 10.1097/mcg.0b013e318238348c↗
  24. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318252f4f5↗
  25. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Co-author DOI 10.1159/000328449↗
  26. Is health screening beneficial for early detection and prognostic improvement in pancreatic cancer? Co-author DOI 10.5009/gnl.2011.5.2.194↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joo Kyung Park · 15 shared papers, 2017–2025 · strength 2.24
  2. Jong Kyun Lee · 15 shared papers, 2012–2025 · strength 1.76
  3. Hye Min Kim · 9 shared papers, 2020–2025 · strength 1.30
  4. Kwang Hyuck Lee · 11 shared papers, 2012–2025 · strength 1.20
  5. Kee‐Taek Jang · 9 shared papers, 2012–2025 · strength 0.95
  6. Jin Ho Choi MD · 5 shared papers, 2024–2025 · strength 0.95
  7. Young Hoon Choi · 5 shared papers, 2023–2025 · strength 0.82
  8. Jin Seok Heo · 4 shared papers, 2022–2025 · strength 0.70
  9. In Woong Han · 4 shared papers, 2022–2025 · strength 0.70
  10. Sang Hyun Shin · 4 shared papers, 2022–2025 · strength 0.70
  11. Jong Kyun Lee · 7 shared papers, 2011–2025 · strength 0.68
  12. Joon Oh Park · 5 shared papers, 2011–2025 · strength 0.57
  13. Semin Lee · 3 shared papers, 2024–2025 · strength 0.57
  14. Hee Chul Park · 4 shared papers, 2012–2025 · strength 0.54
  15. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  16. Hongbeom Kim · 3 shared papers, 2020–2025 · strength 0.48
  17. Youngil Koh · 3 shared papers, 2023 · strength 0.42
  18. Hyung Rae Kim · 3 shared papers, 2023 · strength 0.42
  19. Sung‐Soo Yoon · 3 shared papers, 2023 · strength 0.42
  20. Daechan Park · 3 shared papers, 2023 · strength 0.42
  21. Kangpyo Kim · 2 shared papers, 2024–2025 · strength 0.38
  22. Ji Hye Min · 2 shared papers, 2024–2025 · strength 0.38
  23. Jung Yong Hong · 2 shared papers, 2024–2025 · strength 0.38
  24. Kyunga Kim · 2 shared papers, 2024–2025 · strength 0.37
  25. Dong Hyo Noh · 3 shared papers, 2018–2021 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.